PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 23, 2018Clinical Cancer Research312 citationsOpen Access

Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab

RJRichard W. JosephJEJeroen Elassaiss‐SchaapRKRichard Kefford

Key Points

  • Determine whether baseline tumor size acts as an independent prognostic factor for overall survival in patients with melanoma receiving pembrolizumab.
  • Assessed melanoma patients undergoing immunotherapy with pembrolizumab.
  • Measured pretreatment baseline tumor dimensions and correlated tumor burden with clinical survival outcomes.
  • Baseline tumor size was established as an independent prognostic factor for overall survival.
  • Patients with smaller baseline tumor burden exhibited significantly improved overall survival compared to those with larger baseline tumors.

Abstract

.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Joseph et al. (2018) studied this question.

synapsesocial.com/papers/69ff8dba413f0c047f2d6686https://doi.org/10.1158/1078-0432.ccr-17-2386
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Development of a Prototype Immunohistochemistry Assay to Measure Programmed Death Ligand-1 Expression in Tumor Tissue2016 · 94 citations
  2. 2Improved Survival with Ipilimumab in Patients with Metastatic Melanoma2010 · 15,280 citations
  3. 3LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951)2009 · 138 citations
  4. 4Toxicity and response criteria of the Eastern Cooperative Oncology Group1982 · 11,785 citations
  5. 5Final Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma2001 · 2,664 citations